Renal Protective Effects of Leukotriene Receptor Blockers in an Experimental Model of Cyclosporine Nephrotoxicity

Transplantation Proceedings

Volumn 40, Issue 1, 2008, Pages 279-284

  Atakan, A ^a   Arikan, H ^a   Macunluoglu, B ^a   Tuglular, S ^a   Ulfer, G ^a   Cakalagaoglu, F ^a   Ozener, C ^a   Akoglu, E ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MONTELUKAST; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; IMMUNOHISTOCHEMISTRY; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION;

ACETATES; ADMINISTRATION, ORAL; ANIMALS; CYCLOSPORINE; DIURESIS; GLOMERULAR FILTRATION RATE; KIDNEY; LEUKOTRIENE ANTAGONISTS; MALE; PROTEINURIA; QUINOLINES; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38749127161     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.11.026     Document Type: Article

References (41)

1. Cook D. Long term survival of kidney allografts. In: Terasaki P.I. (Ed). Clinical Transplantation (1987), UCLA Tissue Typing Laboratoy, Los Angeles 277
2. Opelz G., Schwarz V., Engelman A., et al. Long term HLA matching on kidney graft survival in cyclosporine treated recipient. Transplant Proc 23 (1991) 373
3. Paul L.C., and Benediksson H. Chronic transplant rejection: magnitude of problem and pathogenetic mechanisms. Transplant Rev 7 (1993) 96
4. Bennet W.M. The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 43 (1995) S3
5. Moena F.M., Hostetter T.H., Salahudeen A.K., et al. progression of kidney disease in chronic renal transplant rejection. Transplantation 52 (1991) 239
6. Perico N., Ruggenetti P., Gaspari F., et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 564 (1992) 56
7. Remuzzi G., and Perico N. Cyclosporine induced renal dysfunction in experimental animals and humans. Kidney Int 48 suppl 52 (1995) S70
8. Skorecki K.I., Rutledge W.P., and Schreier R.W. Acute cyclosporine nephrotoxicity-prototype for a renal membrane signaling disorder. Kidney Int 42 (1992) 1
9. Murray B.M., Paller M.S., and Ferris T.F. Effects of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 28 (1985) 766
10. Bennet W.M., Mattos A., Meyer M., et al. Chronic cyclosporine nephrotoxicity: the Achilles heel of immunosuppressive therapy. Kidney Int 50 (1996) 1089
11. Ruiz P., Kolbeck P.C., Scrogos M.W., et al. Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies. Transplantation 45 (1988) 91
12. Mihatsch M.J., Ryffel B., and Gudat F. The differential diagnosis between rejection and cyclosporine nephrotoxicity. Kidney Int 48 suppl 52 (1995) S63
13. 2 receptor antagonists on cyclosporine A renal vasoconstriction. Am J Physiol 267 (1994) F443
14. Bobadilla N.A., Tapia E., Franco M., et al. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporine nephrotoxicity. Kidney Int 46 (1994) 773
15. Perico N., Dadan J., and Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in rat. J Am Soc Nephrol 1 (1990) 76
16. Shehata M., El Nahas A.M., Barkworth E., et al. Increased platelet derived growth factor in the kidneys of cyclosporine treated rats. Kidney Int 46 (1994) 726
17. Pichler R.H., Francheschini N., Young B.A., et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 6 (1995) 1186
18. Mason J., Muller-Schweinietzer E., Dupont M., et al. Cyclosporine and renin angiotensin system. Kidney Int 39 suppl 32 (1991) S28
19. Kagami S., Border W.A., Miller D.E., et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor beta expression in rat glomerular mesangial cell. J Clin Invest 93 (1994) 2431
20. Shihab F.S., Andoh T.F., Tanner A.M., et al. Role of transforming growth factor beta in experimental cyclosporine nephrotoxicity. Kidney Int 49 (1996) 1141
21. Shihab F.S., Bennet W.M., Isaac J., et al. Angiotensin regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity. Kidney Int 62 (2002) 422
22. Butterly W.D., Spurney F., Ruiz P., et al. A role for leukotrienes in cyclosporine nephrotoxicity. Kidney Int 57 (2000) 2586
23. 2 and leukotriene C4 and D4 in mediating cyclosporine induced acute renal failure. Transplantation 52 (1991) 873
24. Lewis R., Austen K., and Soberman R. Leukotrienes and other products of the 5-lipooxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 323 (1990) 645
25. Johnson M., Carey F., and Mcmillan R.M. Alternate pathways of arachidonate metabolism: prostaglandins, thromboxane and leukotrienes. In: Campbell P.N., and Marshall R.D. (Eds). Essays in Biochemistry (1983), Academic Press, New York 498
26. Samuelson B., Dahlen S., and Elindgren J.A. Leukotrienes and lipoxins. structures, biosynthesis and biological effects. Science 237 (1987) 1171
27. Breyer M.D., and Badr K. Arachidonic acid metabolites and the kidney. In: Brenner B.M. (Ed). The Kidney (1996), Saunders Press, Philadelphia
28. 4 production in normal rat glomeruli. Nephrol Dial Transplant 2 (1987) 154
29. Baud L., Sraer J., and Delarue F. Lipooxygenase prodcts mediate the attachment of rat macrophages to glomeruli in vitro. Kidney Int 27 (1985) 855
30. 4 in the rat. Circ Res 54 (1984) 492
31. 4. Can J Physiol Pharmacol 61 (1983) 325
32. 4 binds to human glomerular epithelial cells and promotes their proliferation in vitro. J Clin Invest 76 (1985) 374
33. Badr K.F. Five lipooxygenase products in glomerular immune injury. J Am Soc Nephrol 3 (1992) 907
34. Epstein F.H., Border W.A., and Noble N. Transforming growth factor-β in tissue fibrosis. N Engl J Med 331 (1994) 1286
35. Brady H.R., Persson U., and Ballermann B.J. Leukotrienes stimulate neutrophil adhesion to mesangial cells. Modulation with lipoxins. Am J Physiol 259 (1990) F809
36. Lianos E.A., Noble B., and Hucke B. Glomerular leukotriene synthesis in Heymann-nephritis. Kidney Int 36 (1989) 998
37. Fauler J., Wiemeyer A., and Marx K.H. LT B4 in nephrotoxic serum nephritis in rats. Kidney Int 36 (1989) 46
38. Ferrera N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56 (1999) 794
39. Pilmore H., Erris J.M., Painter D., et al. Vascular endothelial growth factor expression in chronic allograft rejection. Transplantation 67 (1999) 929
40. Amemiya T., Susamura T., and Mifune M. Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int 56 (1999) 2025
41. Clauss M., Gerlach M., Gerlach H., et al. Vascular permeability factor: a tumour derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration. J Exp Med 172 (1990) 1535